Status:
COMPLETED
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.
Eligibility Criteria
Inclusion
- Diagnosed with asthma since at least 6 months prior to first visit
- Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit
- At least one asthma exacerbation more than one but less than twelve months prior to first visit
Exclusion
- Respiratory infection affecting asthma within 30 days before first visit
- Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit
- Any significant disease or disorder that may jeopardize the safety of the patient
- Additional inclusion and exclusion criteria will be evaluated by the Investigator.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT00242775
Start Date
May 1 2005
End Date
May 1 2006
Last Update
January 24 2011
Active Locations (143)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mar del Plata, Buenos Aires, Argentina
2
Research Site
Monte Grande, Buenos Aires, Argentina
3
Research Site
Córdoba, Córdoba Province, Argentina
4
Research Site
Santa Fé, Santa Fe Province, Argentina